A study on the treatment of Parkinson's disease and cognitive impairment with multiple system atrophy by intranasal injection of insulin
DOI:
https://doi.org/10.54097/h36x9j92Keywords:
Intranasal, insulin, Parkinson’s disease, UPDRS, MoCA, Multiple system atrophy.Abstract
Parkinson's disease (PD) and multiple system atrophy (MSA) are both common neurodegenerative diseases. To investigate the effects of intranasal insulin injection on motor function and cognitive impairment in patients with Parkinson's disease (PD) and multiple system atrophy (MSA).Thirteen PD patients and one MSA patient participated in the experiment . Using a random number table method, the participants were assigned to an experimental group (n=8) and a control group (n=6). The experimental group received insulin injection, while the control group received physiological saline injection. Both groups received nasal injection for 4 consecutive weeks. Compare the general information, language fluency (FAS), Montreal Cognitive Assessment Scale (MoCA), Beck Depression Inventory (BDI), and Parkinson's Unified Rating Scale (UPDRS) results between the two groups. Compared to the control group, the experimental group had a significantly higher FAS score, but there was no significant difference in the FAS score before and after treatment in the experimental group, and the prognosis score improved compared to before. In the experimental group, a MSA patient showed improvement in FAS scores during the four week treatment period, with no significant progression of the disease. There was no significant improvement in UPDRS score, BDI score, and MoCA score before and after treatment, the difference was not significant statistically. The use of insulin therapy for cognitive and motor disorders related to PD is safe and feasible. Intranasal insulin may improve functional motor function and cognitive performance in Parkinson's disease.
Downloads
References
Zhang Liang, Liao Yongqun, Xia Qinchuan, Zhou Shitong, Li Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
Dorszewska J, Kowalska M, Prendecki M, et al. Oxidative stress factors in Parkinson’s disease [J]. Neural regeneration research, 2021, 16(7): 1383.
Xing T, Ma J, Jia C, et al. Neurogenic lower urinary tract dysfunction predicts prognosis in patients with multiple system atrophy[J]. Clinical Autonomic Research, 2020, 30: 247-254.
Takahashi M, Yamada T, Tooyama I, et al. Insulin receptor mRNA in the substantia nigra in Parkinson's disease [J]. Neuroscience letters, 1996, 204(3): 201-204.
Xing T, Ma J, Jia C, et al. Neurogenic lower urinary tract dysfunction predicts prognosis in patients with multiple system atrophy[J]. Clinical Autonomic Research, 2020, 30: 247-254.
Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain [J]. Nature neuroscience, 2002, 5(6): 514-516.
Li Yao, Guo Zhenzhen, Hu Shuang, et al The Sinicization and Reliability and Validity Test of the Parkinson's Disease Caregiver Burden Scale [J] Chinese Nurse Research, 2022, 36 (8)
Vial F, Delgado I, Idiaquez J F, et al. Epidemiology of Parkinson’s disease in Chile [J]. Neuroepidemiology, 2021, 55(5): 393-397.
Bosco D, Plastino M, Cristiano D, et al. Dementia is associated with insulin resistance in patients with Parkinson's disease[J]. Journal of the neurological sciences, 2012, 315(1-2): 39-43.
Athauda D, Gulyani S, kumar Karnati H, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial[J]. JAMA neurology, 2019, 76(4): 420-429.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







